查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916934

噬菌体疗法试剂盒市场：按试剂盒类型、给药方法、产品类型、应用和最终用户划分－全球预测（2026-2032 年）

Phage Therapy Kits Market by Kit Type, Delivery Method, Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年噬菌体疗法试剂盒市值为 4.2813 亿美元，预计到 2026 年将成长至 5.2092 亿美元，年复合成长率为 21.73%，到 2032 年将达到 16.9624 亿美元。

主要市场统计数据
基准年 2025 4.2813亿美元
预计年份：2026年 5.2092亿美元
预测年份：2032年 1,696,240,000 美元
复合年增长率 (%) 21.73%

噬菌体疗法试剂盒的整合实施：重点介绍标准化试剂和工作流程如何促进研究、临床和工业领域的转化科学

噬菌体疗法试剂盒正与微生物学、基因组学和临床实践的进步相融合，形成一套快速成熟的工具，用于辅助发现、诊断和治疗应用开发。这些试剂盒整合了试剂、对照品和通讯协定，可在研究、临床和工业环境中实现噬菌体的可重复分离、纯化、定量和定序。随着科学界和监管相关人员探索传统抗菌药物的替代方案，基于噬菌体的方法正从学术研究走向实际应用，这需要使用标准化的高品质试剂盒来确保结果的一致性。

快速的技术创新、临床领域日益增长的兴趣以及跨产业的应用，正在将噬菌体疗法试剂盒领域重塑为一个更标准化和可扩展的生态系统。

噬菌体疗法试剂盒市场正经历着变革性的转变，这主要得益于技术的成熟、临床需求的成长以及跨领域的应用。定序技术和高效能检测方法的进步提高了噬菌体鑑定的准确性和速度，而纯化和定量试剂的改进则降低了实验室间的差异。因此，供应商正致力于创新，提供承包解决方案，降低非专业实验室的进入门槛，并加速研发和产品开发的迭代週期。

评估近期关税对实验室耗材和试剂盒采购、供应链策略以及供应商选择的商业性影响。

2025年实施的关税政策调整为噬菌体疗法试剂盒的生产商、分销商和采购商带来了新的考量。某些实验室耗材和试剂关税的提高增加了依赖跨境供应链的企业的到岸成本，促使采购团队重新评估筹资策略和总到岸成本。为此，许多生产商和经销商正在探索近岸外包、双重采购和策略性库存布局等策略，以降低关税波动带来的风险，并确保关键组件（例如专用缓衝液和对照品）的持续供应。

全面的細項分析揭示了应用领域、套件类型、最终用户、交付方式和产品类型如何相互交织，从而塑造未满足的需求和供应商差异化。

在评估噬菌体疗法试剂盒的产品定位、研发重点领域和商业化部署时，了解市场区隔至关重要。按应用领域划分，需求主要来自农业领域，重点关注作物和牲畜病原体控制；食品安全项目，寻求可靠的病原体检测和检验；研究活动涵盖基础研究到商业研发；以及针对感染疾病、肿瘤应用和伤口护理干预的治疗开发渠道。在研究领域，基础研究优先考虑平台的多功能性和发现试剂，而商业性研发则强调可重复性和监管文件。治疗应用进一步细分为传染病领域，例如胃肠道感染疾病和医院获得性感染疾病，以及将噬菌体生物学与辅助性治疗相结合的肿瘤和伤口护理专案。

区域战略趋势和业务要务表明，美洲、欧洲、中东和非洲以及亚太地区需要差异化的产品、监管和分销方法。

区域趋势将对噬菌体疗法试剂盒的推广管道、监管预期和商业策略产生重大影响。在美洲，强大的生物技术创新中心、广泛的临床试验活动以及对替代抗菌药物较为开放的法规环境，为研究驱动型和转化型试剂盒的推广应用创造了有利条件。该地区还需要可扩展的供应链和强有力的售后支持，以服务包括学术机构、临床机构和商业终端用户在内的多元化用户层。

主要企业层面深入洞察产品检验、品质系统和策略伙伴关係关係如何创造竞争优势并影响临床和研究买家的采纳情况。

噬菌体疗法试剂盒的竞争格局呈现出多元化的特点，包括专业试剂生产商、拓展噬菌体相关工作流程的成熟仪器製造商，以及提供小众高性能解决方案的专业供应商。主要企业凭藉其深厚的技术检验、提供临床和研究级文件的能力，以及支援上下游工作流程的广泛产品生态系统脱颖而出。此外，那些投资于完善的品管系统、批次级可追溯性和清晰使用说明的企业，更有利于被诊断中心和生物製药开发公司采用。

为产业领导者提供切实可行的建议，以加强检验、实现供应链多元化并提高客户参与，从而推动噬菌体疗法试剂盒的持续普及应用。

为了抓住噬菌体试剂盒生态系统中的机会，产业领导者应优先采取措施，增强技术可靠性、供应链韧性和客户参与。首先，投资于完善的检验包装，包括临床和研究级别的文件、批间性能数据以及第三方对比测试。这些材料将降低受监管终端用户的采用门槛，并加速其融入转换工作流程。其次，实现生产和分销地点的多元化，以降低关税风险和海关延误，并制定替代采购方案，以确保关键试剂的持续供应。

本文介绍了依证的调查方法，该方法结合了相关人员访谈、文献综述和分析框架，以确保研究结果具有可操作性和检验。

本报告整合了第一手和第二手调查方法，以确保分析的严谨性和对实践者的实用性。第一手研究包括对生物製药研发部门、诊断实验室、医院采购团队、学术研究团队和农业科学领域的相关人员进行结构化访谈。这些访谈重点在于影响试剂盒选择和使用的技术要求、检验预期、采购行为和物流限制。此外，与生产和分销专家的讨论也提供了关于供应链韧性、品质保证实践和监管文件需求的实用观点。

本文全面探讨了噬菌体疗法试剂盒不断变化的作用，以及企业应利用哪些策略槓桿来推动其在研究、临床和应用领域的成功应用。

总之，噬菌体疗法试剂盒作为一种平台技术，在科研创新、临床应用和病原体控制的交叉领域中发挥着至关重要的作用。定序、纯化和定量技术的进步降低了技术门槛，拓宽了噬菌体工具的可靠应用范围。同时，关税变化、复杂的供应链和各地区不同的监管要求等商业性现实，要求生产商和采购商都应做出深思熟虑的策略性回应。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 噬菌体疗法试剂盒市场（按试剂盒类型划分）

  • 完整套装
  • 消耗品
  • 试剂组
    • 控制
      • 阴性对照
      • 阳性对照
    • 裂解缓衝液
    • 染色试剂

9. 依给药途径分類的噬菌体疗法试剂盒市场

  • 注射
    • 肌肉内注射
    • 静脉注射
    • 皮下注射
  • 口服
  • 外用

第十章 噬菌体疗法试剂盒市场（依产品类型划分）

  • 诊断试剂盒
  • 净化套装
  • 定量试剂盒
    • 斑块检测试剂盒
    • qPCR试剂盒
      • 探针底座套件
      • SYBR 绿色套件
  • 定序试剂盒

第十一章 噬菌体疗法试剂盒市场依应用领域划分

  • 农业
  • 食品安全
  • 研究
    • 基础研究
    • 商业研发
  • 治疗
    • 感染疾病
      • 胃肠道感染疾病
      • 院内感染
    • 肿瘤学
    • 伤口护理

第十二章 噬菌体疗法试剂盒市场（依最终用户划分）

  • 生物製药公司
  • 诊断中心
  • 医院
  • 研究所
    • 学术机构
    • CRO（受託研究机构）
      • 临床服务
      • 临床前服务

第十三章 噬菌体疗法试剂盒市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 噬菌体疗法试剂盒市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国噬菌体疗法试剂盒市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国噬菌体疗法试剂盒市场

第十七章：中国噬菌体疗法试剂盒市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Adaptive Phage Therapeutics, Inc.
  • Armata Pharmaceuticals, Inc.
  • BiomX, Inc.
  • ContraFect Corporation
  • Eliava BioPreparations LTD
  • Eligo Bioscience SAS
  • Fixed-Phage Limited
  • Intralytix, Inc.
  • iNtRON BIoTechnology, Inc.
  • Locus Biosciences, Inc.
  • Micreos BV
  • Microgen
  • Phagelux, Inc.
  • Pherecydes Pharma SAS
  • Technophage
Product Code: MRR-AE420CB15404

The Phage Therapy Kits Market was valued at USD 428.13 million in 2025 and is projected to grow to USD 520.92 million in 2026, with a CAGR of 21.73%, reaching USD 1,696.24 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 428.13 million
Estimated Year [2026] USD 520.92 million
Forecast Year [2032] USD 1,696.24 million
CAGR (%) 21.73%

An integrative introduction to phage therapy kits highlighting how standardized reagents and workflows are enabling translational science across research, clinical, and industrial domains

Phage therapy kits are converging with advances in microbiology, genomics, and clinical practice to create a rapidly maturing suite of tools that support discovery, diagnostics, and therapeutic application development. These kits bundle reagents, controls, and protocols to enable reproducible isolation, purification, quantification, and sequencing of bacteriophages across research laboratories, clinical settings, and industrial environments. As scientific and regulatory stakeholders seek alternatives to traditional antimicrobials, phage-based approaches have transitioned from academic curiosity to practical workflows that require standardized, high-quality kits for consistent results.

Moreover, the interplay between research-driven innovation and translational application has intensified demands on kit manufacturers to provide integrated solutions that address variability in sample matrices, sensitivity requirements, and downstream analytical platforms. Consequently, collaborators across biopharmaceutical R&D, diagnostic developers, and agricultural hygiene teams are increasingly reliant on kits that reduce technical barriers and accelerate experimental reproducibility. Transitioning from proof-of-concept to routine use, these kits are being adapted for therapeutic development pipelines, hospital infection control programs, food safety verification, and basic and commercial research workflows.

In this context, stakeholders must navigate evolving technical expectations, regulatory considerations, and operational deployment challenges. This executive summary synthesizes critical trends, regulatory headwinds, segmentation insights, and pragmatic recommendations to inform strategic planning for organizations engaging with phage therapy kits in research, clinical, and applied domains.

How rapid technical advances, expanding clinical interest, and cross-sector adoption are reshaping the phage therapy kits landscape into a more standardized and scalable ecosystem

The landscape for phage therapy kits is undergoing transformative shifts driven by technological maturation, heightened clinical interest, and cross-sector adoption. Advances in sequencing and high-throughput assays have increased the fidelity and speed of phage identification, while improved purification and quantification reagents have reduced variability between laboratories. As a result, kit vendors are innovating to deliver turnkey solutions that lower the barrier to entry for non-specialist labs and accelerate iterative cycles of R&D and product development.

Concurrently, clinical stakeholders are pushing for more standardized diagnostic and therapeutic workflows. This demand fuels development of kits tailored to clinical validation and regulatory submission paths, which in turn prompts suppliers to incorporate robust controls and traceable reagents. At the same time, agricultural and food safety actors are embracing phage-based tools for pathogen surveillance and contamination control, prompting diversification of kit portfolios to address varied sample types and regulatory regimes.

Transitioning from niche research tools to broadly deployable platforms, the ecosystem now emphasizes interoperability with common laboratory instruments, modular kit architectures, and digital support resources such as protocol repositories and data analysis pipelines. Taken together, these dynamics are fostering a more predictable and scalable environment for kit adoption, while also increasing competitive pressure on providers to demonstrate quality, reproducibility, and regulatory awareness.

Assessing the practical commercial implications of recent tariff measures that are reshaping procurement, supply chain strategies, and vendor selection for laboratory consumables and kits

Tariff policy changes implemented in 2025 have introduced new considerations for companies that manufacture, distribute, or procure phage therapy kits. Increased duties on certain laboratory consumables and reagents have raised landed costs for organizations that rely on cross-border supply chains, prompting procurement teams to reassess sourcing strategies and total landed expense. In response, many manufacturers and distributors are exploring nearshoring, dual-sourcing, and strategic inventory placement to mitigate exposure to tariff volatility and to preserve continuity of supply for critical components such as specialized buffers and control materials.

Additionally, tariffs have indirectly influenced supplier selection criteria by elevating the importance of localized regulatory compliance, lead-time reliability, and supplier transparency. As a consequence, purchasers are placing higher value on vendors that can demonstrate robust quality management systems, clear supply chain traceability, and regional distribution footprints that reduce customs complexity. Meanwhile, research laboratories and clinical centers are adapting purchasing workflows to account for extended procurement cycles and potential customs delays, and they are increasing engagement with vendors on forecasting and contractual assurances.

Ultimately, while tariffs have not altered the scientific rationale for phage approaches, they have become a material commercial factor. Companies that proactively redesign supply chains, diversify manufacturing locations, and provide clear logistics support will be better positioned to sustain customer relationships and operational resilience under shifting trade conditions.

Comprehensive segmentation insights revealing how application, kit type, end user, delivery method, and product type intersect to shape unmet needs and supplier differentiation

Understanding segmentation is critical when evaluating product positioning, R&D focus, and commercial outreach for phage therapy kits. Based on application, demand originates from agricultural contexts focused on pathogen control in crops and livestock, food safety programs seeking reliable pathogen detection and verification, research activities that span both basic research and commercial R&D, and therapeutic development pathways targeting infectious diseases, oncology applications, and wound healing interventions. Within the research segment, basic research prioritizes platform versatility and exploratory reagents, while commercial R and D emphasizes reproducibility and regulatory-grade documentation. Therapeutic applications fragment further into infectious disease workstreams such as gastrointestinal infections and hospital-acquired infections as well as specialized oncology and wound healing programs that integrate phage biology with adjunctive therapies.

Based on kit type, product portfolios include complete kits designed for end-to-end workflows, consumables intended for routine laboratory use, and reagent kits focused on specific assay components. Reagent offerings typically comprise controls, lysis buffers, and staining reagents, with controls themselves differentiated into negative and positive controls to support assay validation and quality assurance. Each kit type implies differing expectations for documentation, shelf life, and lot-to-lot consistency, which informs manufacturing and QA investments.

Based on end user, adoption patterns vary among biopharmaceutical companies that require GMP-aware inputs, diagnostic centers and hospitals that favor clinical-grade performance, and research laboratories including academic institutions and contract research organizations. Within contract research organizations, service lines split into clinical services and preclinical services, each demanding distinct product attributes and support infrastructures.

Based on delivery method, therapeutic and experimental applications use injection routes such as intramuscular, intravenous, and subcutaneous administration, as well as oral and topical formulations, which dictate formulation stability and sterility requirements. Finally, based on product type, instruments and consumables align to diagnostic kits, purification kits, quantification kits, and sequencing kits. Quantification tools often involve plaque assay kits and qPCR kits, with the latter subdividing into probe-based and SYBR Green chemistries, each imposing distinct assay design and validation needs. Integrating these segmentation lenses clarifies where unmet needs persist and where suppliers can differentiate through tailored product specifications, regulatory-grade documentation, and customer-centric service models.

Regional strategic dynamics and operational imperatives highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific demand differentiated product, regulatory, and distribution approaches

Regional dynamics materially influence adoption pathways, regulatory expectations, and commercial strategies for phage therapy kits. In the Americas, robust biotech innovation hubs, extensive clinical trial activity, and a receptive regulatory environment for alternative antimicrobials create fertile conditions for both research-oriented and translational kit adoption. This region also demands scalable supply chains and strong post-market support to serve a mixture of academic, clinical, and commercial end users.

In Europe, Middle East & Africa, diversity across regulatory regimes and healthcare infrastructures necessitates flexible go-to-market approaches. Western European countries with established phage research traditions emphasize rigorous clinical validation, while emerging markets within the region may prioritize cost-effective solutions and simple operational footprints. Stakeholders in this region frequently require multilingual regulatory documentation and collaboration with local distributors to navigate heterogeneous market access pathways.

In the Asia-Pacific region, rapid growth in biotechnology research, sizable agricultural sectors, and expanding clinical research capacity drive demand across multiple kit categories. Manufacturers aiming to scale here must accommodate a wide array of laboratory instrument platforms, localized quality standards, and pricing expectations. Across all regions, local partnerships, regional manufacturing or distribution hubs, and proactive regulatory engagement improve market access and support long-term customer relationships. Recognizing these regional particularities enables suppliers to tailor product specifications, support offerings, and commercial models to match customer expectations and operational realities.

Key company-level insights on how product validation, quality systems, and strategic partnerships create competitive advantage and influence adoption among clinical and research buyers

The competitive environment for phage therapy kits features a mix of specialized reagent manufacturers, instrument incumbents expanding into phage-relevant workflows, and boutique providers offering niche, high-performance solutions. Leading suppliers differentiate through depth of technical validation, availability of clinical- or research-grade documentation, and the breadth of their product ecosystems that support upstream and downstream workflows. In addition, companies that invest in robust quality management systems, lot-level traceability, and clear instructions for use position themselves more favorably for adoption by diagnostic centers and biopharmaceutical developers.

Strategic partnerships between kit manufacturers and academic or clinical centers accelerate validation and build credibility, while collaborations with distribution networks enhance regional market penetration. Moreover, firms that provide value-added services such as assay optimization, protocol training, and data analysis support increase customer retention and reduce adoption friction. As procurement teams increasingly evaluate total cost of ownership and logistical reliability, vendors that can demonstrate predictable supply, scalable manufacturing, and responsive technical support enjoy a competitive advantage.

Finally, intellectual property around assay chemistries, control materials, and kit configurations remains a differentiating factor. Companies balancing proprietary innovations with open protocols can capture both high-margin specialty segments and broader-volume institutional accounts. Consequently, strategic choices about openness, partnership, and vertical integration will shape competitive positioning over the coming years.

Actionable recommendations for industry leaders to fortify validation, diversify supply chains, and enhance customer engagement to drive durable adoption of phage therapy kits

Industry leaders should prioritize actions that strengthen technical credibility, supply resilience, and customer engagement to capture opportunities within the phage kit ecosystem. First, invest in robust validation packages that include clinical- and research-grade documentation, lot-to-lot performance data, and third-party comparability studies. These materials reduce adoption friction for regulated end users and accelerate integration into translational workflows. Second, diversify manufacturing and distribution footprints to mitigate tariff exposure and customs-related delays, and develop contingency sourcing plans for critical reagents to sustain continuous supply.

Next, elevate post-sale value by offering protocol support, training resources, and optional assay optimization services. This approach not only improves outcomes for users but also fosters long-term relationships and recurring revenue. Furthermore, cultivate strategic collaborations with academic centers, clinical research organizations, and agricultural research partners to validate real-world performance and generate compelling use cases. Simultaneously, refine product portfolios to offer modular kit options that align with differing end-user needs, such as clinical validation, high-throughput research, or field-deployable food safety applications.

Finally, invest in clear regulatory navigation resources and regional market entry plans that account for local compliance expectations. Together, these actions will enhance product trust, reduce procurement barriers, and accelerate uptake across research, clinical, and applied sectors.

An explanation of the evidence-based research methodology combining stakeholder interviews, literature synthesis, and analytical frameworks to ensure actionable and validated insights

This report synthesizes primary and secondary research methodologies to ensure analytical rigor and relevance to practitioners. Primary research includes structured interviews with stakeholders across biopharmaceutical R&D, diagnostic laboratories, hospital procurement teams, academic research groups, and agricultural science units. These interviews focused on technical requirements, validation expectations, procurement behavior, and logistical constraints that influence kit selection and use. In addition, discussions with manufacturing and distribution specialists provided practical perspectives on supply chain resilience, quality assurance practices, and regulatory documentation needs.

Secondary research encompassed a systematic review of peer-reviewed literature, regulatory guidance documents, and industry technical standards relevant to bacteriophage handling, assay development, and therapeutic formulation. The analysis also examined publicly available clinical trial registries, patent filings, and methodological publications to triangulate trends in assay chemistries, sequencing approaches, and quantification strategies. Data synthesis prioritized evidence-based findings, with careful cross-referencing between primary insights and documented technical sources.

Analytical frameworks used in the study include segmentation mapping, supply chain risk assessment, product differentiation matrices, and regulatory readiness evaluation. Throughout the research process, quality control steps involved validation of interview transcripts, cross-validation of technical claims against authoritative references, and iterative review by subject-matter experts to ensure accuracy and practical relevance for decision-makers.

Concluding perspective on the evolving role of phage therapy kits and the strategic levers companies must employ to drive reliable adoption across research, clinical, and applied settings

In conclusion, phage therapy kits occupy a pivotal role as enabling technologies at the intersection of research innovation, clinical translation, and applied pathogen control. Advances in sequencing, purification, and quantification are lowering technical barriers and expanding the contexts in which phage tools can be reliably applied. At the same time, commercial realities such as tariff changes, supply chain complexity, and diverse regional regulatory expectations necessitate thoughtful strategic responses from manufacturers and purchasers alike.

Strategically, organizations that invest in rigorous validation, diversify supply chains, and provide high-touch customer support will reduce adoption friction and build durable market relationships. Meanwhile, segmentation-aware product strategies that align kit types, delivery methods, and end-user requirements will reveal white spaces for differentiation-particularly where clinical-grade documentation, modular workflows, and interoperability with existing lab instrumentation are prioritized. Looking ahead, the confluence of technical maturity and cross-sector demand suggests that phage therapy kits will become standard components of the toolbox for researchers, clinicians, and applied science professionals, provided that vendors continue to emphasize quality, transparency, and regional adaptability.

Ultimately, the path to broader adoption involves not just better products but clearer support structures, regulatory engagement, and logistics solutions that collectively lower operational risk and improve outcomes for end users across sectors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Phage Therapy Kits Market, by Kit Type

  • 8.1. Complete Kits
  • 8.2. Consumables
  • 8.3. Reagent Kits
    • 8.3.1. Controls
      • 8.3.1.1. Negative Controls
      • 8.3.1.2. Positive Controls
    • 8.3.2. Lysis Buffers
    • 8.3.3. Staining Reagents

9. Phage Therapy Kits Market, by Delivery Method

  • 9.1. Injection
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Oral
  • 9.3. Topical

10. Phage Therapy Kits Market, by Product Type

  • 10.1. Diagnostic Kits
  • 10.2. Purification Kits
  • 10.3. Quantification Kits
    • 10.3.1. Plaque Assay Kits
    • 10.3.2. qPCR Kits
      • 10.3.2.1. Probe Based Kits
      • 10.3.2.2. Sybr Green Kits
  • 10.4. Sequencing Kits

11. Phage Therapy Kits Market, by Application

  • 11.1. Agricultural
  • 11.2. Food Safety
  • 11.3. Research
    • 11.3.1. Basic Research
    • 11.3.2. Commercial R And D
  • 11.4. Therapeutic
    • 11.4.1. Infectious Diseases
      • 11.4.1.1. Gastrointestinal Infections
      • 11.4.1.2. Hospital Acquired Infections
    • 11.4.2. Oncology
    • 11.4.3. Wound Healing

12. Phage Therapy Kits Market, by End User

  • 12.1. Biopharmaceutical Companies
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals
  • 12.4. Research Laboratories
    • 12.4.1. Academic Institutions
    • 12.4.2. Contract Research Organizations
      • 12.4.2.1. Clinical Services
      • 12.4.2.2. Preclinical Services

13. Phage Therapy Kits Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Phage Therapy Kits Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Phage Therapy Kits Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Phage Therapy Kits Market

17. China Phage Therapy Kits Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Adaptive Phage Therapeutics, Inc.
  • 18.6. Armata Pharmaceuticals, Inc.
  • 18.7. BiomX, Inc.
  • 18.8. ContraFect Corporation
  • 18.9. Eliava BioPreparations LTD
  • 18.10. Eligo Bioscience SAS
  • 18.11. Fixed-Phage Limited
  • 18.12. Intralytix, Inc.
  • 18.13. iNtRON Biotechnology, Inc.
  • 18.14. Locus Biosciences, Inc.
  • 18.15. Micreos BV
  • 18.16. Microgen
  • 18.17. Phagelux, Inc.
  • 18.18. Pherecydes Pharma SAS
  • 18.19. Technophage

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHAGE THERAPY KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHAGE THERAPY KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHAGE THERAPY KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PHAGE THERAPY KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PHAGE THERAPY KITS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHAGE THERAPY KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMPLETE KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMPLETE KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMPLETE KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY NEGATIVE CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY NEGATIVE CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY NEGATIVE CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY POSITIVE CONTROLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY POSITIVE CONTROLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY POSITIVE CONTROLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY LYSIS BUFFERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY LYSIS BUFFERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY LYSIS BUFFERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY STAINING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY STAINING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY STAINING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PURIFICATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PURIFICATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PURIFICATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PLAQUE ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PLAQUE ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PLAQUE ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PROBE BASED KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PROBE BASED KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PROBE BASED KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SYBR GREEN KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SYBR GREEN KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SYBR GREEN KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SEQUENCING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SEQUENCING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY SEQUENCING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY AGRICULTURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY FOOD SAFETY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY FOOD SAFETY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY FOOD SAFETY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMMERCIAL R AND D, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMMERCIAL R AND D, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY COMMERCIAL R AND D, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITAL ACQUIRED INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITAL ACQUIRED INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITAL ACQUIRED INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL PHAGE THERAPY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 286. GCC PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. GCC PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. GCC PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 289. GCC PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 290. GCC PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 291. GCC PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 292. GCC PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. GCC PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. GCC PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 297. GCC PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 298. GCC PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. GCC PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 301. GCC PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION PHAGE THERAPY KITS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS PHAGE THERAPY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS PHAGE THERAPY KITS MARKET SIZE, BY KIT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS PHAGE THERAPY KITS MARKET SIZE, BY REAGENT KITS, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS PHAGE THERAPY KITS MARKET SIZE, BY CONTROLS, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS PHAGE THERAPY KITS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS PHAGE THERAPY KITS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS PHAGE THERAPY KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS PHAGE THERAPY KITS MARKET SIZE, BY QUANTIFICATION KITS, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS PHAGE THERAPY KITS MARKET SIZE, BY QPCR KITS, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS PHAGE THERAPY KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS PHAGE THERAPY KITS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS PHAGE THERAPY KITS MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS PHAGE THERAPY KITS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS PHAGE THERAPY KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS PHAGE